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Abstract
Introduction: Patients with advanced chronic obstructive pulmonary disease (COPD) are at risk for developing
invasive pulmonary aspergillosis. A clinical algorithm has been validated to discriminate colonization from putative
invasive pulmonary aspergillosis (PIPA) in Aspergillus-positive respiratory tract cultures of critically ill patients. We
focused on critically ill patients with COPD who met the criteria for PIPA.
Methods: This matched cohort study included critically ill patients with COPD from two university hospital
intensive care units (ICUs). We studied the risk factors for PIPA as well as the impact of PIPA on short- and long-
term outcomes. Whether PIPA was associated with a pattern of bacterial colonization and/or infection 6 months
before and/or during ICU stay was assessed. In addition, antifungal strategies were reviewed.
Results: Fifty cases of PIPA in critically ill patients with COPD in the ICU were matched with one hundred control
patients with COPD. The ICU short- and the long-term (at 1 year) mortality were significantly increased in the PIPA
group (p < 0.001 for all variables). PIPA was a strong independent risk factor for mortality in the ICU (odds ratio 7.44,
95 % confidence interval 2.93–18.93, p < 0.001) before vasopressor therapy, renal replacement therapy, and duration
of mechanical ventilation. Before ICU admission, the use of corticosteroids and antibiotics significantly increased the
risk of PIPA (p = 0.004 and p < 0.001, respectively). No significant difference in bacterial etiologic agents responsible
for colonization and/or infection was found between the groups. Antifungal treatment was started in 64 % of PIPA
cases, with a poor impact on the overall outcome.
Conclusions: PIPA was a strong death predictor in critically ill patients with COPD. The use of corticosteroids and
antibiotics before ICU admission was a risk factor for PIPA. PIPA was not associated with a specific bacterial pattern
of colonization or infection. Prompting antifungal treatment in critically ill patients with COPD who have PIPA may
not be the only factor involved in prognosis reversal.
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Introduction
Invasive aspergillosis (IA) is a life-threatening opportun-
istic infection first described during prolonged neutro-
penia [1]. IA is associated with immunocompromised
status that occurs in patients undergoing hematopoietic
stem cell or solid organ transplants, in those with solid
tumors, and in patients receiving corticosteroids [1–3].
In these settings, IA is defined by the European
Organization for Research and Treatment of Cancer/
Mycosis Study Group (EORTC/MSG) as proven, prob-
able, or possible, based on a level of proof ranging from
the decisive histopathological evidence of fungal invasion
(proven) to a set of host risk factors and clinical features
either associated (probable) or not (possible) with the
positivity of mycological criteria [4].
Besides the immunocompromised setting, Aspergillus
spp. can cause invasive disease in other subsets of pa-
tients, including those in intensive care units (ICUs)
who may not fall into the above-described classifications
[5, 6]. The mildly immunocompromised status of many
non-malignant conditions, the nonspecific clinical and
radiological patterns, and the limited value of myco-
logical criteria led to reconsideration of the universal
relevance of EORTC/MSG case definitions. Therefore,
an alternative critically ill patient–adapted algorithm has
been proposed to discriminate Aspergillus colonization
from invasive pulmonary aspergillosis (IPA) [7, 8]. It has
been externally validated by a multicenter study de-
signed to confront the clinical criteria included in the al-
gorithm with histopathology-proven cases of IPA [9].
Altogether, this algorithm has a specificity of 61 % and a
sensitivity of 92 %. For an assumed IPA prevalence of
40 %, the positive and negative predictive values are
61 % and 92 %, respectively.
Chronic obstructive pulmonary disease (COPD) is one
of the most common comorbidities among critically ill
patients. Acute exacerbations cause frequent ICU admis-
sions that may require mechanical ventilation (MV). In
an observational multicenter study of 563 critically ill
patients with proven putative invasive pulmonary asper-
gillosis (PIPA) or Aspergillus colonization, researchers
found that COPD was the most frequent underlying
condition, accounting for almost one-third (31 %, n =
174) of all cases [10]. Making an IPA diagnosis in ICU-
admitted patients with COPD is challenging, as obtain-
ing a lung biopsy is rarely feasible in patients with re-
spiratory insufficiency on one side and Aspergillus spp.
from endotracheal aspirate cultures may reflect colonization
rather than infection on the other side.
We focused on critically ill patients with COPD who
met the criteria for PIPA according to the clinical algo-
rithm. A hypothesis was formulated that the algorithm
may be a relevant tool for predicting the outcome of the
specific subset of critically ill patients with COPD and
PIPA. Using a matched cohort design, we investigated
the short- and long-term outcomes of these patients.
We sought to determine the risk factors for PIPA. In
addition, we tested the hypothesis that PIPA may be as-
sociated with specific respiratory bacterial pathogens.
Antifungal treatment strategies were also reviewed.
Methods
Study patients and case definitions
This retrospective study included critically ill patients
admitted to the ICUs at the university hospitals of Lille
and Lyon, France. Adult patients diagnosed with COPD
according to the Global Initiative for Chronic Obstruct-
ive Lung Disease (GOLD) criteria between January 2006
and December 2013 and associated with a positive cul-
ture for Aspergillus spp. from a lower respiratory tract
(LRT) specimen were identified in the computerized pa-
tient files at the two institutions (Fig. 1). Patients’ data
were collected from a prospectively maintained database
and by additional chart review. Patients eligible for in-
clusion were those who strictly matched the criteria for
the PIPA algorithm [9]. PIPA referred to the presence of
a positive culture for Aspergillus spp. from any LRT sam-
ple, together with meeting three criteria: (1) compatible
signs and symptoms (fever refractory to at least 3 days
of antibiotics, recrudescent fever, pleuritic chest pain or
rub, dyspnea, hemoptysis, or worsening respiratory in-
sufficiency despite adequate treatment), (2) abnormal
medical imaging (chest x-ray or computed tomographic
scan of the lungs), and (3) either host factor (neutro-
penia, underlying hematological or oncological malig-
nancy treated with cytotoxic agents, glucocorticoid
treatment, congenital or acquired immunodeficiency) or
semiquantitative Aspergillus-positive culture of broncho-
alveolar lavage (BAL) fluid, without concurrent bacterial
growth, together with a positive cytological smear
Fig. 1 Flowchart of selected cases. ABPA allergic bronchopulmonary
aspergillosis, COPD chronic obstructive pulmonary disease, CPA
chronic pulmonary aspergillosis, HM hematological malignancy, PIPA
putative invasive pulmonary aspergillosis
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showing branching hyphae. Patients without any clinical
or imaging findings or without host factor or cytological
findings with positive cultures for Aspergillus spp. from
an LRT sample were considered colonized. Patients with
conditions such as chronic pulmonary aspergillosis,
allergic bronchopulmonary aspergillosis, progressive
hematological malignancy, or solid tumor were excluded
(Fig. 1). Serum detection of galactomannan was not used
as a diagnostic criterion in this study.
The control population in this 1:2 matched cohort
study consisted of adult ICU patients with confirmed
COPD and absence of Aspergillus-positive culture in re-
spiratory samples. Cases were matched on age (±5 years),
Simplified Acute Physiology Score (SAPS II) (±5 points),
and ICU length of stay (equal to or more than the case
until the diagnosis of PIPA). The study was approved by
the local ethics committee of each participating center
(Comité d’Ethique, Centre Hospitalier Régional Universi-
taire de Lille et Hospices Civils de Lyon). Because of the
retrospective, observational nature of the study and the
lack of any modification in the general management of
these patients, the need for informed consent was
waived.
Data analysis
The primary objective of this study was to determine the
prognostic factors for PIPA. ICU length of stay, duration
of MV, short-term mortality (in the ICU and at 28 days
after ICU admission), and long-term mortality (at 1 year
after ICU admission) were used as endpoints.
The secondary objective of the study was to determine
the risk factors for PIPA in critically ill patients with
COPD admitted to the ICU. We included the following
variables: demographic variables, underlying diseases,
COPD characteristics, SAPS II and Logistic Organ
Dysfunction System scores upon admission and on the
day of the Aspergillus spp.–positive culture, corticoster-
oid antibiotic use, and supportive therapies. Radiological
and clinical data were collected according to PIPA
criteria [9].
The third objective of the study was to assess whether
PIPA was associated with a pattern of bacterial
colonization or infection 6 months before and during the
ICU stay. The presence of culture-positive sputum or LRT
specimens with the following specific bacterial pathogens
was investigated: respiratory Gram-negative bacteria
(Haemophilus influenzae and Moraxella catarrhalis),
enterobacteria, non-fermenting Gram-negative bacilli
(Pseudomonas spp., Acinetobacter spp., Stenotrophomonas
spp., Burkholderia spp.), and Gram-positive cocci
(Staphylococcus aureus, Streptococcus pneumoniae,
Enterococcus spp.). In addition, antifungal strategies ap-
plied to critically ill patients with COPD in the ICU with
PIPA were examined through the delay of initiation and
the drug(s) chosen for treatment.
Statistical analysis
IBM SPSS software (IBM, Armonk, NY, USA) was used
for data analysis. Categorical variables were described as
frequencies and percentages. The distribution of con-
tinuous variables was tested for normality. Normally
distributed and skewed continuous variables were de-
scribed as mean ± standard deviation or as median and
interquartile range (IQR), respectively. All p values were
two-tailed. Differences were considered significant if p
values were <0.05.
To determine factors associated with PIPA, patients
with PIPA were compared with those without PIPA
using bivariate and multivariate conditional logistic re-
gression analyses. All variables from univariate analysis
with p values <0.1 were incorporated into the multivari-
ate logistic regression analysis. Potential interactions
were tested, and the Hosmer-Lemeshow goodness of fit
was calculated. The odds ratio (OR) and 95 % confi-
dence interval (CI) were calculated for all significant var-
iables in univariate analysis as well as all significant
variables in multivariate analysis.
To determine the impact of PIPA on mortality, survi-
vors and non-survivors among patients with PIPA were
compared using univariate and multivariate analyses.
The χ2 test or Fischer’s exact test was used to compare
qualitative variables, as appropriate. Student’s t test or
the Mann–Whitney U test was used to compare nor-
mally distributed and skewed continuous variables, as
appropriate. All variables from univariate analysis with p
values <0.1 were incorporated into the multivariate lo-
gistic regression analysis. Potential interactions were
tested, and the Hosmer-Lemeshow goodness of fit was
calculated. The OR and 95 % CI were calculated for all
significant qualitative variables in univariate analysis and
for all significant variables in multivariate analysis. Fur-
ther on, the probability of death in the ICU over time
was assessed using the Kaplan-Meier estimate and the
log-rank test.
Univariate analysis between case and control patients
was performed to compare the presence of culture-
positive sputum or LRT specimens with specific bacterial
pathogens. We used a χ2 test or Fisher’s exact test, as ap-
propriate. The OR and 95 % CI were calculated for all
variables. No multivariate regression was performed on
these data.
Results
Patient characteristics and clinical presentation
Fifty cases of PIPA in critically ill-patients with COPD
were identified between 2006 and 2013. These patients
comprised 38 men and 12 women with a median age of
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Table 1 Patient characteristics according to putative invasive pulmonary aspergillosis diagnosis
All patients (n = 150) PIPA (n = 50) No PIPA (n = 100) p Valuea
Number (%) NA (n) Number (%) NA (n) Number (%) NA (n)
Demographics
Male sex, n (%) 111 (74) 38 (76) 73 (73) 0.52
Age, yr (IQR) 66 (60–73) 67 (60–74) 66 (70–73) 0.69
Weight, kg (IQR) 77 (65–94) 19 72 (62–87) 7 78 (67–100) 12 0.098
Underlying conditions, n (%)
Diabetes mellitus 34 (22.7) 8 (16) 26 (26) 0.21
Chronic heart failure 25 (16.7) 11 (22) 14 (14) 0.61
Chronic renal failure 6 (4) 2 (4) 4 (4) 1
Chronic liver failure 8 (5.3) 4 (8) 4 (4) 0.31
Solid tumor (CR) 35 (23.3) 11 (22) 24 (24) 0.74
Hematological malignancy (CR) 5 (3.3) 4 (8) 1 (1) 0.57
Autoimmune disease 6 (4) 3 (6) 3 (3) 0.39
Alcohol abuse 42 (28) 14 (28) 28 (28) 1
COPD characteristics
GOLD grade ≥3, n (% 78 (62.9) 26 31 (68.9) 5 47 (59.5) 21 0.30
FEV1 % (IQR) 41 (29–59) 30 37 (27–57) 8 43 (30–60) 22 0.47
Smoking history, n (%) 135 (93.7) 6 43 (93.5) 4 92 (93.9) 2 0.92
Pack-years (IQR) 40 (30–60) 61 40 (30–58) 19 45 (30–60) 42 0.66
Acute exacerbations,b n (%) 28 (21.7) 21 8 (17.8) 5 20 (23.8) 16 0.54
Corticosteroid use, n (%)
Chronic use >3 mo 22 (14.7) 13 (26) 9 (9) 0.004
Daily dose >20 mg 77 (52.7) 36 (73.5) 41 (42.3) <0.001
Chronic inhalational corticosteroid use 75 (51) 3 28 (56) 47 (48.4) 3 0.52
ICU admission
Antibiotics (prior 3 months) 82 (55.4) 2 40 (83.3) 2 42 (42) <0.001
SAPS II, mean (SD) 46.9 (13.9) 46.9 (13.9) 47 (13.9) 0.99
LODS score (IQR) 6 (4–8) 6 (3–7) 6 (4–8) 0.26
Supportive therapy in ICU
MV duration 14 (5–27) 18 (8–26) 12 (5–26) 0.60
Renal replacement therapy, n (%) 25 (17) 7 (14) 18 (18) 0.57
Vasopressive or inotropic agents, n (%) 95 (63) 32 (64) 63 (63) 0.69
Symptoms, n (%)
Refractory fever 17 (11.3) 6 (12) 11 (11) 0.85
Recrudescence of fever 19 (12.7) 11 (22) 8 (8) 0.02
Pleural effusion 17 (11.3) 6 (12) 11 (11) 0.85
Dyspnea 136 (90.7) 49 (98) 87 (87) 0.07
Hemoptysis 8 (5.3) 5 (10) 3 (3) 0.187
Worsening of respiratory insufficiency 50 (33.3) 30 (60) 20 (20) <0.001
PIPA putative invasive pulmonary aspergillosis, NA not available, IQR interquartile range, CR complete remission, COPD chronic obstructive pulmonary disease,
GOLD Global Initiative for Chronic Obstructive Lung Disease, FEV1 forced expiratory volume in 1 second, MV mechanical ventilation, ICU intensive care unit, SAPS II
Simplified Acute Physiology Score, LODS Logistic Organ Dysfunction System, SD standard deviation
ap < 0.05 was considered statistically significant
bAt least three acute exacerbations or a single one requiring ICU hospitalization over the past year
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67 (IQR 60–74) years at diagnosis. The patients’ baseline
characteristics are summarized in Table 1. As all cases
had positive Aspergillus-LRT cultures, A. fumigatus was
identified as the pathogen in 46 cases (92 %) and other
Aspergillus spp. in 4 cases (8 %). Microscopy of tracheal
aspirates or BAL fluid demonstrated fungal hyphae in 16
(32 %) of 50 samples.
Survival, clinical features, and supportive therapies
associated with PIPA
In univariate analysis, mortality was significantly in-
creased in the PIPA group in comparison with the con-
trol group when we considered either overall ICU
mortality or short-term 28-day mortality (62 % vs. 29 %
and 48 % vs. 16 %, respectively; p < 0.001 for both
variables). The long-term mortality at 1 year after ICU
admission was significantly increased in the PIPA group
in comparison with the control group as well (74 % vs.
36 %, p < 0.001). The Kaplan-Meier statistics showed a
significantly increased probability of death over time
(p < 0.001 by log-rank test) (Fig. 2). The multivariate
analysis confirmed PIPA as being a strong independ-
ent risk factor for mortality in the ICU (OR 7.4, 95 %
CI 2.9–18.9, p < 0.001), as were vasopressor therapy
(OR 5.6, 95 % CI 2.1–15.1, p = 0.001), renal replace-
ment therapy (OR 5.3, 95 % CI 1.6–17.3, p = 0.005),
and longer duration of MV (OR 1 per day of MV,
95 % CI 1–1.1, p = 0.004, Hosmer-Lemeshow
goodness-of-fit test p = 0.798) (Table 2).
Risk factors associated with PIPA
In univariate analysis, the underlying conditions of pa-
tients or their COPD characteristics were not risk factors
for PIPA (Table 1). In multivariate analysis, the use of
corticosteroids for longer than 3 months as well as the
use of antibiotics before ICU admission significantly
increased the risk of PIPA (OR 8, 95 % CI 2–31.9, p <
0.001; and OR 13.4, 95 % CI 4.3–41.8, p < 0.001, respect-
ively; Hosmer-Lemeshow goodness of fit p = 0.824). The
same significant result was obtained when we tested a
prednisone equivalent dose >20 mg/day (data not
shown).
Bacteria-associated colonization or infection
To investigate whether the occurrence of PIPA was asso-
ciated with specific bacterial species, we compared the
colonization or infections occurring in patients with
PIPA and control patients as long as 6 months before
ICU admission (Table 3). Particular attention was paid
to non-fermenting bacterium Pseudomonas aeruginosa,
the presence of which among other Gram-negative bac-
teria was specifically documented. No significant differ-
ence in bacterial colonization or infection was found
between the two groups.
Fig. 2 Kaplan-Meier curves showing survival rate in patients with putative invasive pulmonary aspergillosis (PIPA) and control patients over a
3-month time course after intensive care unit admission. p < 0.001 by log-rank test
Table 2 Risk factors for mortality in ICU in multivariable analysis
Risk factor All patients (n = 150)
OR CI p Valuea
PIPA 7.4 2.9–18.9 <0.001
Vasopressor therapy 5.6 2.1–15.1 0.001
RRT 5.3 1.6–17.3 0.005
Duration of mechanical ventilation 1 1–1.1 0.004
PIPA putative invasive pulmonary aspergillosis, OR odds ratio, CI confidence
interval, RRT renal replacement therapy
ap < 0.05 was considered statistically significant; Hosmer-Lemeshow goodness-of-
fit test p = 0.798
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Antifungal regimen for PIPA
Overall, 32 patients (64 %) received an antifungal ther-
apy, all of which were single-drug regimens. The anti-
mold drugs used were voriconazole (59.4 %, n = 19),
caspofungin, (28.1 %, n = 9), and amphotericin B (3.1 %,
n = 1). Of note, 3 patients (9.4 %) received off-mold
spectrum fluconazole. The median delay of antifungal
treatment initiation was 8 (IQR, 5–11) days after ICU
admission and 4 (IQR, 0–8) days after Aspergillus spp.–
positive LRT specimen. Regarding the outcome of the
treated patients, 20 (62.5 %) died in the ICU and the 1-
year overall mortality rate was 75 % (n = 24). In the
untreated group (n = 18), 11 (64.7 %) died in the ICU
and the 1-year overall mortality rate was 76.5 % (n = 13).
Discussion
We have demonstrated in critically ill patients with
COPD a very significant association between PIPA and
fatal outcome with follow-up of 12 months. PIPA was a
stronger independent death predictor than other major
specific ICU interventions (vasopressor use, renal
replacement therapy, or duration of MV during ICU
stay). In the setting of COPD, the present study confirms
the usefulness of the PIPA algorithm to predict lethal
outcome. A recent study of 297 critically ill patients with
proven IPA or PIPA provided evidence in multivariate
analysis that both MV and renal replacement therapy at
diagnosis were risk factors for mortality [10]. In the
present study, the 1-year mortality rate of 74 % is con-
sistent with two previous COPD-focused case–control
studies, although overall death was evaluated earlier in
both studies (71.6 % at 4 months and 61.5 % at
6 months) [11, 12] than in our study. The use of an anti-
fungal treatment did not make any difference in terms of
short- and long-term mortality with a relatively short
time to treatment initiation after ICU admission, indicat-
ing that prognosis is not exclusively linked to a matter of
promptly implementing the appropriate anti-infectious
treatment against Aspergillus spp. infection but may be
multifactorial, related to overall severity of the patient’s
condition. This point is in accordance with the results of
previous studies showing that GOLD grades 3 and 4 are
likely represented in the probable IPA group rather than
in the Aspergillus spp.–colonized group [12, 13].
The use of antibiotics and high cumulative doses of
corticosteroids significantly increased the risk of PIPA in
critically ill patients with COPD with Aspergillus LRT
cultures, as previously reported [10–16]. An originality
of the present study is that we investigated whether
PIPA occurrence is associated with specific bacterial
communities, since very few data are available on cross-
kingdom interactions. Particularly, we focused on P. aer-
uginosa, which is frequently found in advanced COPD
and is known for its great mutational and biofilm-
producing abilities, conferring increased antibiotic resist-
ance [17]. An in vitro study has demonstrated a com-
petitive inhibition of A. fumigatus biofilm formation by a
set of P. aeruginosa strains [18]. However, the bacterial
vacancy resulting from antibiotics may lead to further
fungal biofilm-organized invasion and decreased suscep-
tibility to antifungal drugs, as Aspergillus spp. has the
ability to form a biofilm [19–21].
Strengths of the present study include a matched co-
hort design and the long-term follow-up of patients with
PIPA. Limitations of the present study include the retro-
spective, nonconsecutive series and the bias resulting
from the low number of enrolling centers as well as the
low number of patients enrolled, PIPA being a rare en-
tity (7.4 % of the critically ill patients with COPD were
screened for the study over an 8-year period, which rep-
resents three cases per ICU per year). As the case fatality
rate is high for ICU patients with COPD with PIPA, the
lack of systematic postmortem autopsy or lung biopsy
for histological confirmation mitigates the evidence-
based value of the algorithm. In addition, mortality
might have been overestimated because of the relatively
small number of patients with PIPA. Stratification of
mortality results according to GOLD grades could not
be performed, owing to too many missing data for func-
tional status at admission. Finally, the small number of
treated patients hampers the conclusions regarding the
Table 3 Bacteria-associated colonization or infection before or
during PIPA
All patients PIPA No PIPA p Valuea




91 (61) 30 (60) 61 (61) 0.725
Gram-negative bacteria, n (%)
Respiratoryb 14 (9) 1 (2) 13 (13) 0.054
Enterobacteria




51 (34) 20 (40) 31 (31) 0.331
Pseudomonas
spp.
38 (25) 14 (28) 24 (24) 0.670
Gram-positive bacteria, n (%)
Staphylococcus
aureus
21 (14) 10 (20) 11 (11) 0.160
Other coccid 21 (14) 5 (10) 16 (16) 0.290
PIPA putative invasive pulmonary aspergillosis
ap < 0.05 was considered statistically significant
bHaemophilus influenzae and Moraxella catarrhalis
cPseudomonas spp., Acinetobacter spp., Stenotrophomonas spp.,
Burkholderia spp.
dStreptococcus pneumoniae, Enterococcus spp.
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impact of antifungal treatment on the outcome. Another
bias related to the treatment is the lack of serum con-
centrations of antifungal drugs administrated to patients
with PIPA, namely voriconazole, the data for which were
not available.
Conclusions
In the setting of critically ill patients with COPD, using a
clinical algorithm designed to discriminate Aspergillus
spp. colonization from PIPA, we could determine that
PIPA was a strong predictor of lethal outcome in
patients with COPD. Our data suggest that implement-
ing an antifungal treatment may not be the only factor
involved in prognosis reversal. PIPA was not associated
with a dominant pattern of bacterial colonization or in-
fection. In the setting of critically ill patients with COPD
and PIPA, further prospective studies are required to as-
sess relevant diagnostic methods, therapeutic support,
and/or interventions in improving outcomes.
Key messages
 PIPA, as defined according to the Blot et al. criteria
[9], is a strong predictor of short- and long-term
lethal outcome in critically ill patients with COPD.
 The use of antibiotics and high cumulative doses of
corticosteroids significantly increased the risk of
PIPA occurrence in critically ill patients with COPD
with Aspergillus lower respiratory tract cultures.
 Prompting antifungal treatment in critically ill
patients with COPD with PIPA may not be the only
factor involved in prognosis reversal.
 PIPA was not associated with a dominant pattern of
bacterial colonization or infection 6 months before
or during fungal infection.
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